

Certificate of Analysis

Lab ID: **TIR-025**

REPORTED August 14, 2026

CLIENT

VERIFY peptidetestcanada.ca/verify

EMAIL info@peptidetestcanada.ca

ORDER # PTC-WJXID7T3

SCAN TO VERIFY



PTC-WP2MH2SC

END CUSTOMER

NAME VPeptide.com

EMAIL —

PHONE —

ADDRESS —

§ 01 Sample Information

FOR RESEARCH PURPOSES ONLY

Sample ID:	TIZ08-0530	Received:	08/11/2026
Compound:	Tirzepatide	Analyzed:	08/14/2026
Report No.:	COA-2026-SC-01262	CAS:	2023788-19-2
Total Mass:	65.6 mg Lyophilized	Formula:	C₂₂₅H₃₄₈N₄₈O₆₈
Appearance:	powder	Mol Weight:	4814.6 g/mol

SAMPLE PHOTOGRAPH



§ 02 Analytical Results

Qualitative and Quantitative chemical analysis by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

	SPECIFICATION	RESULT	STATUS
Compound Test:	Tirzepatide	Tirzepatide	
Net Peptide Content:	30.00 mg	30.39 mg	
Peptide Label Accuracy:	≥ 90 %	101.3 %	PASS
Chromatographic Purity:	≥ 98 %	99.5 %	

Chromatographic purity is the target peptide's HPLC-MS/MS principal component analysis, expressed as a percentage of total integrated peak area (Ph. Eur. 2.2.46) — it bounds peptide-related impurities only, not excipients, counter-ions, or residual water, and is separate from net peptide content. — indicates not determined.

§ 03 LC-MS/MS Detail


METHOD B · AGILENT 1290 INFINITY II + 6495 QQQ · ESI+

PRECURSOR [M+5H]⁵⁺

963.90 Da

Quantifier transition ● MRM

963.90 > 136.10 CE 28 V



ROLE	TRANSITION	CE
● Quantifier	963.9 > 136.1	28 V
■ Qualifier	963.9 > 110.1	33 V

Agilent Poroshell 120 EC-C18 · 2.1×100 mm · 2.7 μm · Solvent A: 0.1 % formic acid in H₂O · Solvent B: 0.1 % formic acid in Acetonitrile

DISCLAIMER · RESEARCH USE ONLY

Results relate **only to the sample as received** and the tests performed — not to any other unit, lot, or batch. **For research use only:** not a certificate of quality, safety, efficacy, or regulatory compliance, and not for human or veterinary administration, clinical or diagnostic use, or label claims. SideChain Analytics does not manufacture, source, or sell the material and makes **no warranty, express or implied**; its liability shall not exceed the testing fee. This report may not be reproduced except in full.

Issued August 14, 2026